iMedicor's CEO and President to Speak with Shareholders
Shareholders Will be Updated on Recently Launched Initiatives, And New Strategic Alliances
NANUET, N.Y.--(BUSINESS WIRE)--iMedicor, (OTCBB: VMCI), today announced that Chief Executive Officer Fred Zolla and President, Tom Dorsett will speak to the company's shareholders on Thursday, November 12, 2009 beginning at 12:00 PM, EST. A brief Q&A will follow the remarks.
To join the call, please visit www.imedicorevents.com/shareholdermeeting for instructions and registration.
About iMedicor, a Vemics Company:
Vemics' iMedicor is the only HIPAA-compliant solution for interoperable medical information transfer that is offered at no cost to healthcare providers. The iMedicor portal also enables pharmaceutical companies to deliver customized marketing programs to more than 730,000 healthcare providers nationwide in a highly targeted, cost-effective and non-intrusive manner. iMedicor also allows doctors, administrators and other qualified healthcare workers to send and receive medical records, files and images and enables disparate EMR (electronic medical record) systems to communicate, collaborate and exchange records in real time. More information on iMedicor is available at www.imedicor.com.
The statements contained herein, other than historical information, are or may be deemed to be forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance of Vemics' products and services; the nonexclusive and terminable-at-will nature of certain of the company's partnerships and agreements; rapid technological change affecting demand for our products and services; competition from companies providing similar products and services, availability of sufficient financial resources to enable us to expand our operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission.








